Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Pancreatic Neoplasms 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Genetic Predisposition to Disease 1Gallbladder Neoplasms 1Colorectal Neoplasms 1

Interventions

fludarabine phosphate 21Cyclophosphamide 20Peripheral Blood Stem Cell Transplantation 19Busulfan 16Tacrolimus 14Whole-Body Irradiation 12Methotrexate 12Mycophenolic Acid 11Cyclosporine 11Antilymphocyte Serum 10fludarabine 6Filgrastim 6peginterferon alfa-2a 5ruxolitinib 4Radiotherapy 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Decitabine 4Aspirin 4Stem Cell Transplantation 3Injections 3Cytogenetic Analysis 3Cytarabine 3Biopsy 3Azacitidine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3merphos 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocythemia, Essential × Mutation × Clear all
NCT06923670 2025-05-15

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase NA Not yet recruiting
496 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡